Roche (RO.SW) announced that the European Commission has granted conditional marketing authorisation of Lunsumio, or mosunetuzumab, subcutaneous for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. Approval is based on results from the phase I/II GO29781 study. Phase III studies involving Lunsumio SC are ongoing.
Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said: "Developing new formulations of our medicines is part of our commitment to offering greater flexibility and a better treatment experience for patients."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.